Gene · 22925
Papers2,349
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
81 to 100 of 2,349
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Clinical profile and outcome of primary membranous nephropathy: A tertiary care center experience from North India. | World J Nephrol | 2026 | 41884230 | PubTator, text mining | PubMed |
| A rare case of renal cancer with PLA2R-positive membranous nephropathy and AL amyloidosis: Insights into mechanisms and treatment. | Clin Nephrol | 2026 | 41879484 | PubTator, text mining | PubMed |
| MHC class II and PLA2R investigating the epitope presentation deficits driving antibody production in membranous nephropathy. | Int Urol Nephrol | 2026 | 41870742 | PubTator, text mining | PubMed |
| Long-term outcomes in primary membranous nephropathy: a Chinese cohort study with novel target antigen. | Front Immunol | 2026 | 41869300 | PubTator, text mining | PubMed |
| A rare overlap: an image of ANCA-associated glomerulonephritis superimposed on membranous nephropathy. | J Bras Nefrol | 2026 | 41861388 | PubTator, text mining | PubMed |
| Diabetes mellitus attenuates response to anti-CD20 therapy in primary membranous nephropathy despite equivalent B-cell depletion. | Nephrol Dial Transplant | 2026 | 41860432 | PubTator, text mining | PubMed |
| The lipid-podocyte axis: emerging clues in membranous nephropathy pathogenesis. | Front Med (Lausanne) | 2026 | 41859161 | PubTator, text mining | PubMed |
| Optimized RTX strategy plus structured glucocorticoid tapering for primary membranous nephropathy: a multicenter propensity score-matched cohort study. | Front Mol Biosci | 2026 | 41858735 | PubTator, text mining | PubMed |
| Obinutuzumab for membranous nephropathy: a systematic review using pooled case-level extraction analysis. | Acta Clin Belg | 2026 | 41852044 | PubTator, text mining | PubMed |
| ATP2C2-PLA2R1 axis underlies lipid metabolism modulation and invasion in papillary thyroid carcinoma mediated by a VGIC signature. | Discov Oncol | 2026 | 41845134 | PubTator, text mining | PubMed |
| PLA2R-positive primary membranous nephropathy in an adolescent with type 1 diabetes mellitus and autoimmune hypothyroidism: a case report. | CEN Case Rep | 2026 | 41838286 | PubTator, text mining | PubMed |
| Identification of Hub Genes Associated With Oxidative Stress of Acute Kidney Injury via Machine Learning Algorithm. | Nephrology (Carlton) | 2026 | 41834116 | PubTator, text mining | PubMed |
| Anti-PLA2R1 IgG-mediated podocyte PLA2R1 cleavage drives glomerular subepithelial immune complex deposition in membranous nephropathy. | Kidney Int | 2026 | 41833639 | PubTator, text mining | PubMed |
| Hyperlipidemia in membranous nephropathy. | Clin Kidney J | 2026 | 41822057 | PubTator, text mining | PubMed |
| Cancer Incidence and Risk Factors in PLA2R-Associated Membranous Nephropathy. | Mayo Clin Proc | 2026 | 41790079 | PubTator, text mining | PubMed |
| Rituximab for the treatment of immune checkpoint inhibitor-induced glomerulonephritis. | Clin Kidney J | 2026 | 41788614 | PubTator, text mining | PubMed |
| Intermittent White Urine With Nephrotic-Range Proteinuria and Preserved Renal Function: A Diagnostic Dilemma Between Chyluria, Pseudochyluria, and Amyloidosis. | Cureus | 2026 | 41788110 | PubTator, text mining | PubMed |
| A New Perspective on Predicting PLA2R-Associated Membranous Nephropathy Relapse: The Value of a Genetic Risk Score. | J Inflamm Res | 2026 | 41767900 | PubTator, text mining | PubMed |
| Concomitant immunoglobulin A nephropathy and membranous nephropathy with Fabry-like zebra bodies: A case report and literature review. | Medicine (Baltimore) | 2026 | 41759999 | PubTator, text mining | PubMed |
| Obinutuzumab in the treatment of idiopathic refractory membranous nephropathy: an observational case series. | Front Med (Lausanne) | 2026 | 41756365 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/22925/papers?page=5